What Changed
Price Move History
- Daily moves over 5%
- 23 252 sessions, November 17, 2025 to November 17, 2026
- Largest daily move
- -35.2% close of March 25, 2026
- 1-year change
- -2% closing prices, November 17, 2025 to November 17, 2026
- 1-month change
- +19.4% closing prices, October 16, 2026 to November 17, 2026
Company Description
Maze Therapeutics, Inc. (Nasdaq: MAZE) is a clinical-stage biopharmaceutical company that focuses on developing small molecule precision medicines for patients with kidney and metabolic diseases, including obesity. According to the company’s public disclosures, Maze harnesses the power of human genetics to guide drug discovery and development, aiming to translate genetic insights into targeted therapies for clearly defined patient groups.
Maze is headquartered in South San Francisco, California and operates in the biotechnology industry within the healthcare sector. The company’s common stock is listed on The Nasdaq Stock Market under the ticker symbol MAZE, as noted in its SEC filings. Maze describes itself as a clinical-stage organization, meaning its lead drug candidates are in human clinical trials rather than commercial use.
Genetics-Driven Drug Discovery and the Compass Platform
Maze reports that its research and development engine is built around its proprietary Compass™ platform. The platform is designed to identify and characterize genetic variants associated with disease and then link those variants to the biological pathways that drive disease in specific patient groups. In its filings and press releases, Maze refers to this process as variant functionalization.
By integrating variant discovery with functional studies, Maze seeks to prioritize genetically validated targets for small molecule drug development. The company states that Compass is intended to inform multiple phases of the drug development process, including target selection and clinical trial design. Maze emphasizes that its goal is to use this genetics-based approach to discover and advance programs with first- or best-in-class potential in kidney and metabolic diseases.
Therapeutic Focus: Kidney and Metabolic Diseases
Across its public communications, Maze consistently describes its focus on kidney and metabolic diseases, including obesity and inherited metabolic disorders. The company highlights chronic kidney disease (CKD) and APOL1-mediated kidney disease (AMKD) as key areas of interest within nephrology, as well as phenylketonuria (PKU) within metabolic medicine.
Maze notes that AMKD is a subset of CKD that is estimated to affect over one million people in the United States alone. The company also references a broader CKD population that includes patients who inadequately respond to currently available therapies. In metabolic disease, Maze focuses on PKU, an inherited disorder characterized by elevated phenylalanine levels, and indicates that its approach is intended to be independent of specific genotypes or phenylalanine hydroxylase activity.
Lead Program: MZE829 for APOL1-Mediated Kidney Disease
Maze’s most advanced program, as described in its S-1 registration statement and press releases, is MZE829, an oral, small molecule inhibitor of apolipoprotein L1 (APOL1). MZE829 is being developed for patients with APOL1-mediated kidney disease (AMKD), which the company identifies as a genetically defined subset of CKD.
The company characterizes MZE829 as a dual-mechanism APOL1 inhibitor and notes that it is in Phase 2 clinical development. Maze is enrolling patients in the Phase 2 HORIZON trial, described as an open-label basket design study. According to Maze, this trial includes AMKD patients who carry two high-risk APOL1 alleles (G1 or G2) and covers a broad range of clinical phenotypes, including:
- Patients with diabetic kidney disease
- Patients with non-diabetic kidney disease, such as hypertensive nephropathy
- Patients with severe focal segmental glomerulosclerosis (FSGS) and nephrotic-level proteinuria
Maze states that the HORIZON trial is intended to generate proof-of-concept data in this genetically defined population. Earlier Phase 1 data, as summarized in the S-1, indicated that MZE829 was evaluated in healthy volunteers across a range of doses, with Maze reporting that treatment was well tolerated at the doses tested and that pharmacokinetics were dose-proportional with relatively low variability.
Second Lead Program: MZE782 for PKU and Chronic Kidney Disease
The company’s second lead program is MZE782, described as an investigational, potent, oral inhibitor of SLC6A19, a sodium-dependent neutral amino acid transporter expressed in the small intestine and proximal tubule of the kidney. Maze is advancing MZE782 for two indications:
- Phenylketonuria (PKU), an inherited metabolic disorder
- Chronic kidney disease (CKD), including patients who may not respond adequately to existing CKD therapies
According to Maze, SLC6A19 plays a key role in the absorption and reabsorption of neutral amino acids, including phenylalanine (Phe). In PKU, SLC6A19 enables Phe uptake from the gut and reabsorption in the kidney, both of which contribute to elevated plasma Phe levels in patients with deficient phenylalanine hydroxylase activity. Maze explains that inhibiting SLC6A19 with MZE782 offers a genotype- and PAH-agnostic oral approach to lowering plasma Phe by limiting its entry into circulation.
In CKD, Maze states that SLC6A19-mediated reabsorption may contribute to metabolic overload in the kidney’s proximal tubule. By blocking this transporter, MZE782 may reduce the burden of amino acids and toxins, which Maze suggests could potentially slow disease progression. The company notes that this mechanism is complementary to, and distinct from, SGLT2 inhibition.
MZE782 has completed a Phase 1 randomized, double-blind, placebo-controlled study in healthy adult volunteers, as detailed in Maze’s press releases. Maze reports that MZE782 was well tolerated across all tested doses, with no serious adverse events observed. The company also reports dose-dependent increases in urinary excretion of phenylalanine and glutamine, which it interprets as evidence of target engagement and SLC6A19 inhibition. In addition, Maze notes that a dose-dependent initial dip in estimated glomerular filtration rate (eGFR) was observed, similar in magnitude to changes seen with certain renoprotective therapies, and that this effect reversed after dosing stopped.
Based on these findings, Maze has stated its intention to advance MZE782 into Phase 2 proof-of-concept trials in both PKU and CKD, with trial designs focusing on plasma Phe reduction in PKU and proteinuria reduction in CKD.
Broader Pipeline and Partnerships
Beyond its two lead programs, Maze references additional research and discovery efforts that also rely on its Compass platform. Public financial disclosures note prior license agreements, including an exclusive license with Shionogi & Co., Ltd. for rights to MZE001, an investigational oral glycogen synthase 1 (GYS1) inhibitor aimed at addressing Pompe disease by limiting disease-causing glycogen buildup. Maze has also disclosed an exclusive license agreement with Trace Neuroscience, Inc. for a discovery research program targeting UNC13A for the potential treatment of amyotrophic lateral sclerosis.
These collaborations illustrate that Maze’s genetics-guided approach has been applied to multiple therapeutic areas beyond its wholly owned kidney and metabolic programs, although the company’s current clinical focus, as described in its more recent communications, centers on MZE829 and MZE782.
Corporate and Capital Markets Profile
Maze Therapeutics is incorporated in Delaware, as indicated in its S-1 filing. The company identifies itself as an emerging growth company and a smaller reporting company under U.S. securities laws. Its common stock trades on The Nasdaq Global Market under the symbol MAZE.
In September 2025, Maze entered into a securities purchase agreement for an oversubscribed private placement of common stock and pre-funded warrants. The company’s press release and related Form 8-K state that the private placement was expected to generate gross proceeds of approximately $150 million, before fees and expenses. Maze has indicated that it intends to use these proceeds, together with existing cash, to advance MZE829 in AMKD, initiate Phase 2 trials of MZE782 in PKU and CKD, continue research programs, and further develop the Compass platform.
Maze subsequently filed a registration statement on Form S-1 to register the resale of shares issued in the private placement and shares underlying the pre-funded warrants. The S-1 describes the company’s business, risk factors, and clinical programs, and confirms that Maze’s common stock is listed on Nasdaq under the MAZE ticker.
Position Within Biotechnology and Therapeutic Areas
Within the biotechnology sector, Maze positions itself as a clinical-stage precision genetics company focused on kidney and metabolic diseases. Its public materials emphasize:
- Use of human genetics to select and validate drug targets
- Development of oral small molecule therapies rather than biologics
- Concentration on renal indications such as AMKD and CKD
- Expansion into metabolic and inherited disorders such as PKU and obesity-related conditions
Maze’s approach, as described in its filings and press releases, is to align therapeutic development with genetic evidence, aiming to match specific mechanisms—such as APOL1 inhibition or SLC6A19 inhibition—to well-defined patient populations.
Stock Performance
Maze Therapeutics (MAZE) closed at $32.87 on November 17, 2026. Over the past 12 months, the price has lost 2.0%.
MAZE Metrics & Rankings
Price returns through November 17, 2026. Month and year figures include the first trading day. Ranking links may use different dates.
Latest News
Maze Therapeutics has 10 recent news articles. Of the recent coverage, 6 articles coincided with positive price movement and 4 with negative movement. Key topics include earnings, conferences, management, offering, clinical trial. View all MAZE news →
SEC Filings
Maze Therapeutics has filed 10 recent SEC filings, including 4 Form 4, 2 Form 144, 2 Form 8-K, 1 Form SCHEDULE 13G/A. The most recent filing was submitted on . SEC filings provide transparency into a company's financial condition, material events, and regulatory compliance. View all MAZE SEC filings →
Insider Radar
Insider selling at Maze Therapeutics over the past 90 days can reflect routine portfolio management, scheduled trading plans (Rule 10b5-1), tax planning, or compensation-related dispositions rather than a directional view on the stock.
Financial Highlights
Maze Therapeutics reported operating income of -$142.9M in FY2025, and net income was -$131.1M. Diluted earnings per share stood at -$3.05. The company generated -$111.9M in operating cash flow. The current ratio was 15.50, measuring current assets divided by current liabilities.
Upcoming Events
Evercore fireside chat
HORIZON pivotal target
CIPheR topline results
MZE782 CKD trial
Pivotal trial planned
MZE782 Phase 2 data
Trial initiations 2027
MZE829 final data
Pivotal trial start
CIPheR topline data
Maze Therapeutics has 10 upcoming scheduled events. The next event, "Evercore fireside chat", is scheduled for December 1, 2026 (in 13 days). Investors can track these dates to stay informed about potential catalysts that may affect the MAZE stock price.
Short Interest History
Short interest in Maze Therapeutics (MAZE) currently stands at 6.7 million shares, down 11.2% from the previous reporting period, representing 13.7% of the float. Since November 2025, short interest has increased by 201.0%.
Days to Cover History
Days to cover for Maze Therapeutics (MAZE) currently stands at 8.8 days, down 13.2% from the previous period. The ratio is the reported short interest divided by the average daily trading volume. Since November 2025, the figure has increased by 53.1%. Across the settlements charted above, it has ranged from 2.4 to 16.2 days.
MAZE Company Profile & Sector Positioning
Maze Therapeutics (MAZE) operates in the Biotechnology industry within the broader Healthcare sector and is listed on the NASDAQ.
Investors comparing MAZE often look at related companies in the same sector, including Zenas BioPharma, Inc. (ZBIO), Zymeworks Inc. (ZYME), Nurix Therapeutics, Inc. (NRIX), Recursion Pharmaceuticals, Inc. (RXRX), and Trevi Therapeutics, Inc. (TRVI). Comparing financial metrics, valuation ratios, and stock performance across these peers can help investors evaluate MAZE's relative position within its industry.